149 related articles for article (PubMed ID: 21720836)
1. [Benefit assessment by the Federal Joint Committee: assessment of treatment strategies for low risk prostate cancer].
Schmedders M; Janatzek S; Zimmer B
Urologe A; 2011 Aug; 50(8):938-43. PubMed ID: 21720836
[TBL] [Abstract][Full Text] [Related]
2. [Acting in concert: comments on the article by M. Schmedders et al on different therapy approaches for prostate cancer with low risks].
Stöckle M
Urologe A; 2011 Aug; 50(8):944-5. PubMed ID: 21720830
[No Abstract] [Full Text] [Related]
3. Brachytherapy for prostate cancer: a systematic review of clinical and cost effectiveness.
Norderhaug I; Dahl O; Høisaeter PA; Heikkilä R; Klepp O; Olsen DR; Kristiansen IS; Waehre H; Bjerklund Johansen TE
Eur Urol; 2003 Jul; 44(1):40-6. PubMed ID: 12814673
[TBL] [Abstract][Full Text] [Related]
4. [Localised prostate cancer: the PREFERE trial].
Stöckle M; Bussar-Maatz R
Z Evid Fortbild Qual Gesundhwes; 2012; 106(5):333-5; discussion 335. PubMed ID: 22818151
[TBL] [Abstract][Full Text] [Related]
5. A systematic overview of radiation therapy effects in prostate cancer.
Nilsson S; Norlén BJ; Widmark A
Acta Oncol; 2004; 43(4):316-81. PubMed ID: 15303499
[TBL] [Abstract][Full Text] [Related]
6. [Brachytherapy for Prostate Cancer: Potentials and Limitations of Social Health Insurance Data for Benefit Assessment].
Horenkamp-Sonntag D; Linder R; Engel S; Verheyen F
Gesundheitswesen; 2016 May; 78(5):298-305. PubMed ID: 26021371
[TBL] [Abstract][Full Text] [Related]
7. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.
Laviana AA; Ilg AM; Veruttipong D; Tan HJ; Burke MA; Niedzwiecki DR; Kupelian PA; King CR; Steinberg ML; Kundavaram CR; Kamrava M; Kaplan AL; Moriarity AK; Hsu W; Margolis DJ; Hu JC; Saigal CS
Cancer; 2016 Feb; 122(3):447-55. PubMed ID: 26524087
[TBL] [Abstract][Full Text] [Related]
8. [Radiation therapy for prostate cancer in the new S3 guideline. Part 2: postoperative radiation therapy and brachytherapy].
Martin T; Wenz F; Böhmer D; Sedlmayer F; Hinkelbein W; Henkel TO; Miller K; Wiegel T
Urologe A; 2010 Feb; 49(2):216-20. PubMed ID: 20180062
[TBL] [Abstract][Full Text] [Related]
9. Additional treatments and reimbursement rates associated with prostate cancer treatment for patients undergoing radical prostatectomy, interstitial brachytherapy, and external beam radiotherapy.
Goharderakhshan RZ; Grossfeld GD; Kassis A; Shinohara K; Roach M; Carroll PR
Urology; 2000 Oct; 56(4):622-6. PubMed ID: 11018618
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of treatments for patients with localized prostate cancer in Europe: a systematic review.
Becerra V; Ávila M; Jimenez J; Cortes-Sanabria L; Pardo Y; Garin O; Pont A; Alonso J; Cots F; Ferrer M;
BMC Health Serv Res; 2016 Oct; 16(1):541. PubMed ID: 27716267
[TBL] [Abstract][Full Text] [Related]
11. The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base.
Martin JM; Handorf EA; Kutikov A; Uzzo RG; Bekelman JE; Horwitz EM; Smaldone MC
Cancer; 2014 Jul; 120(14):2114-21. PubMed ID: 24737481
[TBL] [Abstract][Full Text] [Related]
12. Low-dose rate brachytherapy for men with localized prostate cancer.
Peinemann F; Grouven U; Hemkens LG; Bartel C; Borchers H; Pinkawa M; Heidenreich A; Sauerland S
Cochrane Database Syst Rev; 2011 Jul; (7):CD008871. PubMed ID: 21735436
[TBL] [Abstract][Full Text] [Related]
13. [Radiotherapy for prostate cancer].
Stanek C
Wien Med Wochenschr; 2007; 157(7-8):149-52. PubMed ID: 17492410
[TBL] [Abstract][Full Text] [Related]
14. Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials.
Peinemann F; Grouven U; Bartel C; Sauerland S; Borchers H; Pinkawa M; Heidenreich A; Lange S
Eur Urol; 2011 Nov; 60(5):881-93. PubMed ID: 21763066
[TBL] [Abstract][Full Text] [Related]
15. [Lack of evidence of benefit - using the example of low dose rate brachytherapy for the treatment of localised prostate carcinoma].
Schmedders M; Dettloff M
Z Evid Fortbild Qual Gesundhwes; 2010; 104(6):512-4. PubMed ID: 20951960
[TBL] [Abstract][Full Text] [Related]
16. [Cost comparison of three treatments for localized prostate cancer in Spain: radical prostatectomy, prostate brachytherapy and external 3D conformal radiotherapy].
Becerra Bachino V; Cots F; Guedea F; Pera J; Boladeras A; Aguiló F; Suárez JF; Gallo P; Murgui L; Pont A; Cunillera O; Pardo Y; Ferrer M;
Gac Sanit; 2011; 25(1):35-43. PubMed ID: 21316126
[TBL] [Abstract][Full Text] [Related]
17. [Introduction of interdisciplinary prostate cancer centers based on the recommendations of the German Cancer Society. A cost-benefit analysis 3 years after accreditation].
Weikert S; Baumunk D; Stephan C; Cash H; Jahnke K; Steiner U; Werthemann P; Kempkensteffen C; Magheli A; Hinz S; Jagota A; Reichelt U; Busch J; Klopf C; Miller K; Schostak M
Urologe A; 2011 Sep; 50(9):1083-8. PubMed ID: 21728009
[TBL] [Abstract][Full Text] [Related]
18. Does brachytherapy have a role in the treatment of prostate cancer?
Grimm PD; Blasko JC; Ragde H; Sylvester J; Clarke D
Hematol Oncol Clin North Am; 1996 Jun; 10(3):653-73. PubMed ID: 8773503
[TBL] [Abstract][Full Text] [Related]
19. [Radiation therapy for prostate cancer in the new S3 guideline. Part 1: localized and locally advanced prostate cancer].
Böhmer D; Wenz F; Martin T; Sedlmayr F; Hinkelbein W; Wiegel T
Urologe A; 2010 Feb; 49(2):211-5. PubMed ID: 20180061
[TBL] [Abstract][Full Text] [Related]
20. Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid.
van Tol-Geerdink JJ; Willem Leer J; Weijerman PC; van Oort IM; Vergunst H; van Lin EN; Alfred Witjes J; Stalmeier PF
BJU Int; 2013 Apr; 111(4):564-73. PubMed ID: 22882966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
